(ALC) Alcon - Ratings and Ratios
IOLs, Contact Lenses, Surgical Equipment, Diagnostic Instruments
Dividends
| Dividend Yield | 0.42% |
| Yield on Cost 5y | 0.53% |
| Yield CAGR 5y | 7.93% |
| Payout Consistency | 99.5% |
| Payout Ratio | 11.7% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.6% |
| Value at Risk 5%th | 37.8% |
| Relative Tail Risk | -6.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.35 |
| Alpha | -22.00 |
| CAGR/Max DD | 0.18 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.330 |
| Beta | 0.724 |
| Beta Downside | 0.670 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.24% |
| Mean DD | 9.06% |
| Median DD | 8.49% |
Description: ALC Alcon December 03, 2025
Alcon Inc. (NYSE: ALC) is a Swiss-based, global eye-care company that designs, manufactures, and markets surgical and vision-care products. It operates through two primary segments – Surgical and Vision Care – and serves ophthalmologists, optometrists, and consumers worldwide.
The Surgical segment supplies a full suite of intra-ocular devices and operating-room equipment, including the Centurion and LenSx laser platforms, Verion digital marking system, ARGOS biometer, NGENUITY 3-D visualization, and a range of intra-ocular lenses (monofocal, toric, and presbyopia-correcting) plus delivery systems such as AutonoMe. The Vision Care segment offers daily-disposable and reusable contact lenses, color-enhancing lenses, ocular-health products (dry-eye, glaucoma, allergy treatments), and over-the-counter items like ocular vitamins and redness relievers.
According to Alcon’s FY 2023 earnings release, the company generated approximately **$8.5 billion** in revenue, with the Surgical segment contributing roughly 55 % and Vision Care 45 %. Operating margin was about **19 %**, reflecting continued cost-discipline after the 2019 spin-off from Novartis. R&D spend averaged **$1.2 billion** (≈14 % of revenue), underscoring a focus on next-generation laser and imaging technologies.
Key economic drivers for Alcon include the **global aging population**, which is expanding the cataract surgery market at an estimated **5 % CAGR** through 2030, and rising demand for refractive procedures such as LASIK, buoyed by higher disposable income in emerging markets. Reimbursement trends and regulatory approvals (e.g., FDA clearance of new IOL platforms) materially affect adoption rates and pricing power.
Sector-wide, the ophthalmic-device industry is experiencing **consolidation** (e.g., recent mergers among premium IOL manufacturers) and a **technology acceleration cycle**, where incremental innovations in femtosecond lasers and AI-driven surgical planning can generate pricing premiums. Base-rate analysis suggests that companies with a diversified product mix and strong aftermarket consumables, like Alcon, tend to outperform pure-equipment peers during periods of macro-economic uncertainty.
For a deeper, data-driven assessment of Alcon’s valuation dynamics, consider exploring the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.05b TTM) > 0 and > 6% of Revenue (6% = 611.1m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 0.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.79% (prev 39.58%; Δ -6.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 2.05b > Net Income 1.05b (YES >=105%, WARN >=100%) |
| Net Debt (3.74b) to EBITDA (1.77b) ratio: 2.11 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (495.9m) change vs 12m ago -0.36% (target <= -2.0% for YES) |
| Gross Margin 55.12% (prev 55.50%; Δ -0.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.93% (prev 32.15%; Δ 0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.76 (EBITDA TTM 1.77b / Interest Expense TTM 199.8m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 61.97
| 1. Piotroski 5.50pt |
| 2. FCF Yield 3.69% |
| 3. FCF Margin 15.05% |
| 4. Debt/Equity 0.24 |
| 5. Debt/Ebitda 2.11 |
| 6. ROIC - WACC (= -5.35)% |
| 7. RoE 4.77% |
| 8. Rev. Trend 93.85% |
| 9. EPS Trend 57.18% |
What is the price of ALC shares?
Over the past week, the price has changed by -0.40%, over one month by +6.47%, over three months by +0.10% and over the past year by -9.75%.
Is ALC a buy, sell or hold?
- Strong Buy: 15
- Buy: 6
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 95.2 | 20.5% |
| Analysts Target Price | 95.2 | 20.5% |
| ValueRay Target Price | 80.4 | 1.8% |
ALC Fundamental Data Overview November 25, 2025
P/E Trailing = 36.481
P/E Forward = 22.4215
P/S = 3.7089
P/B = 1.6792
P/EG = 2.1266
Beta = 0.694
Revenue TTM = 10.19b USD
EBIT TTM = 751.7m USD
EBITDA TTM = 1.77b USD
Long Term Debt = 4.54b USD (from longTermDebt, last fiscal year)
Short Term Debt = 648.3m USD (from shortTermDebt, last quarter)
Debt = 5.23b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.74b USD (from netDebt column, last quarter)
Enterprise Value = 41.51b USD (37.78b + Debt 5.23b - CCE 1.50b)
Interest Coverage Ratio = 3.76 (Ebit TTM 751.7m / Interest Expense TTM 199.8m)
FCF Yield = 3.69% (FCF TTM 1.53b / Enterprise Value 41.51b)
FCF Margin = 15.05% (FCF TTM 1.53b / Revenue TTM 10.19b)
Net Margin = 10.28% (Net Income TTM 1.05b / Revenue TTM 10.19b)
Gross Margin = 55.12% ((Revenue TTM 10.19b - Cost of Revenue TTM 4.57b) / Revenue TTM)
Gross Margin QoQ = 55.78% (prev 53.47%)
Tobins Q-Ratio = 1.32 (Enterprise Value 41.51b / Total Assets 31.49b)
Interest Expense / Debt = 0.97% (Interest Expense 51.0m / Debt 5.23b)
Taxrate = 16.25% (46.0m / 283.0m)
NOPAT = 629.5m (EBIT 751.7m * (1 - 16.25%))
Current Ratio = 2.12 (Total Current Assets 6.33b / Total Current Liabilities 2.99b)
Debt / Equity = 0.24 (Debt 5.23b / totalStockholderEquity, last quarter 22.06b)
Debt / EBITDA = 2.11 (Net Debt 3.74b / EBITDA 1.77b)
Debt / FCF = 2.44 (Net Debt 3.74b / FCF TTM 1.53b)
Total Stockholder Equity = 21.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.32% (Net Income 1.05b / Total Assets 31.49b)
RoE = 4.77% (Net Income TTM 1.05b / Total Stockholder Equity 21.93b)
RoCE = 2.84% (EBIT 751.7m / Capital Employed (Equity 21.93b + L.T.Debt 4.54b))
RoIC = 2.37% (NOPAT 629.5m / Invested Capital 26.58b)
WACC = 7.72% (E(37.78b)/V(43.01b) * Re(8.68%) + D(5.23b)/V(43.01b) * Rd(0.97%) * (1-Tc(0.16)))
Discount Rate = 8.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.27%
[DCF Debug] Terminal Value 79.40% ; FCFE base≈1.45b ; Y1≈1.79b ; Y5≈3.06b
Fair Price DCF = 93.72 (DCF Value 46.03b / Shares Outstanding 491.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 57.18 | EPS CAGR: 9.61% | SUE: 0.46 | # QB: 0
Revenue Correlation: 93.85 | Revenue CAGR: 5.36% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.83 | Chg30d=-0.014 | Revisions Net=-3 | Analysts=9
EPS next Year (2026-12-31): EPS=2.22 | Chg30d=-0.284 | Revisions Net=-7 | Growth EPS=+4.3% | Growth Revenue=+7.2%
Additional Sources for ALC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle